Plus Therapeutics announced on February 20, 2025, the appointment of Michael Rosol, Ph.D., as Chief Development Officer. Dr. Rosol will be responsible for leading the company’s clinical, pre-clinical, and biomarker development activities.
Dr. Rosol brings 25 years of experience in clinical trial design, operations, and regulatory execution. His background includes senior executive roles at Navidea Biopharmaceuticals and leadership positions in biomarker development at Novartis Pharmaceuticals.
This appointment is a strategic move as Plus Therapeutics moves from mid-stage to pivotal trials in the coming year. Dr. Rosol's expertise is expected to align with the company's clinical development plans and path to FDA approval.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.